Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials

Purpose: To investigate the impact of programmed death-ligand 1 (PD-L1) expression, oncogenic mutations, and clinical characteristics on survival after treatment with anti-PD-1/PD-L1 antibodies versus chemotherapy in non-small cell lung cancer (NSCLC). Patients and Methods: This meta-analysis includ...

Full description

Bibliographic Details
Main Authors: Qingyuan Huang, Hua Zhang, Josephine Hai, Mark A. Socinski, Eric Lim, Haiquan Chen, Justin Stebbing
Format: Article
Language:English
Published: Taylor & Francis Group 2018-12-01
Series:OncoImmunology
Subjects:
anti-pd-1
atezolizumab
immunotherapy
nivolumab
non-small cell lung cancer
pembrolizumab
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1396403

Internet

http://dx.doi.org/10.1080/2162402X.2017.1396403

Similar Items